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Abstract 
Background: Multiple sclerosis is considered as an autoimmune disease of the central nervous system that is the 
main cause of disability in young adults around the world. The purpose of this study was to determine changes in 
antibodies in the prognosis of multiple sclerosis, and the use of antibody against aquaporin 4 for the diagnosis of 
multiple sclerosis. Materials and Methods: In this case - control study, 21 patients with a definite diagnosis of 
multiple sclerosis and 21 healthy subjects were selected as the study population.  Blood and urine samples were 
collected, and nephelometry technique was used to assess the presence or absence of IgG, IgM and IgA in serum and 
urine samples. ELISA method for measuring of antibodies against aquaporin 4 was used. Results: There was no 
major difference in  the mean of the total IgM  in the case and control groups , but the mean IgA and IgG levels in 
the control group were  evidently higher than in the case group.  It was releaved that IgA, RBC and Hb mean 
differences between the two groups are statistically significant.  Parallel with an increase in IgG, the probability of 
disease exacerbation was increased by 0.22, whereas with increasing ages, the probability of disease exacerbation 
was 15.0. There was also a positive and significant relationship between the average level of antibodies, IgG and 
IgM with the degree of illness However, the relationship between the mean serum IgA level and the degree of 
illness was inverse. It also became clear that antibodies against AQP-4 in serum and urine of patients with 
different degrees of illness showed no significant difference.  The difference between the mean of antibodies 
against AQP in the serum of patients with mild and moderate MS was 54.1, but in mild and severe MS   it was 
53.3. Conclusion: The findings of this research suggest that serum antibody levels are directly related to the disease 
levels and can be used as a prognostic factor. Accordingly, it appears that the use of antibodies against aquaporin-4 
in serum and urine for the diagnosis of this disease   can be considered as a reliable approach. 
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Multiple Sclerosis (MS) is an inflammatory, 
recurrent and progressive disease of the central 
nervous system that leads to progressive neurological 
dysfunction. Due to  the  disability caused by this 
disease in young and aged people and also  a growing 
global epidemic particularly in Iran, MS is considered 
important [1, 2]. The etiology of MS is unknown, but 
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some factors such as genetic and environmental 
factors, infectious agents and immunological factors 
are involved in the MS pathogenesis [3]. It is well 
known that the clinical course of MS in patients is 
unpredictable, and   it varies in severity from mild to 
the progressive form [4, 5]. In this regard, the clinical 
course in MS patients is classified into 4 groups; 
relapsing- remitting, secondary progressive, primary 
progressive and progressive – relapsing [6] which are 
used   to determine the prognosis and treatment of the 
disease. Studies in Iran suggest that in 64.4% of 
patients, the clinical course has been the relapsing - 
remitting type [7]. On the other hand, despite the 
determining role of T lymphocytes in the MS 
development, other studies suggest that antibody-
dependent mechanisms are also involved in the 
immunopathogenesis of the disease [8]. Numerous 
studies have indicated the role of antibodies against 
various antigens in the diagnosis and prognosis of 
MS, like that of Markus Reindi,   which disclosed the 
use of antibodies as important biomarkers in the 
determination and prognosis of MS [9]. Also, it has 
been reported an increase in IgG and IgM antibodies 
against neurofilament [10]. In another study   it was 
shown an increase in anti-aquaporin 4 (anti-AQP-4) 
antibody in optical neuromyelitis, which is an 
autoimmune inflammatory disease similar to MS [11, 
12]. Aquaporin 4 (AQP-4) is a water channel that 
leads to the passage of water across the cell 
membrane [13]. Additionally, many studies have 
shown that there a is relationship between production 
of antibodies in MS and the disease prognosis [14, 
15]. Another study  also showed that the increase in 
IgM antibodies in the cerebrospinal fluid may play a 
prognostic role in MS [16], whereas other studies did 
not find the relationship between antibody profile 
and MS prognosis [17, 18]. In summary, despite 
numerous studies regarding  the changes in antibody 
levels in MS patients, the results of some studies 
were inconclusive, and  most studies  have been 
focused on  the use of antibodies against various 
antigens  while  few are related to the anti-AQP-4 
antibody  prognostic  role in MS  prognosis [16- 20]. 
Hence, the aim of this study was to determine 
changes in antibodies in the prognosis of multiple 
sclerosis, and the use of antibody against AQP-4  for 
the diagnosis of MS. 
Methods 
In this case-control study, 21 patients with a 
definite diagnosis of MS disease and 21 healthy 
subjects were selected and a complete questionnaire 
on demographic information (age, sex, education, 
occupation), patient records, onset of symptoms, 
method of diagnosis, other diseases, disease 
progression, the classification of the onset of 
symptoms (sensory, motor, visual, etc.) was 
completed. Then, with the consent of the patient, 5 ml 
of blood sample and 5 ml of urine sample were taken. 
The presence or absence of IgG, IgM and IgA, in the 
total serum and urine samples was assessed by 
Nephelometry technique and Immunoglobulin 
measurement kit (binding sit). Nephelometer model 
was NOAD 2000 Mini nephelometr. Also anti-AQP-4 
antibodies were measured by (ELISA 
Kit/Human/Aquaporin 4 Antibody) MyBioSource. 
Then the Optical density (ODs) of six standard 
solutions prepared with different concentrations (0, 
3.0, 2.1, 5.2, 5 and 10 µl/ml) was measured in a 
wavelength of 450 nm using ELISA reader (2100 fax, 
Awareness Technology Inc Company). Standard 
curves were then drawn using the concentrations of the 
different solutions and the standard ODs. To determine 
the concentration of test samples, the OD of each 
sample was placed on the standard curve, and 
concentration estimation was performed.  
  Sample size calculations. The sample size, 
considering   a test power of 90%, and a 5% error 
margin, with the variance б2=12 for IgG variable,   and 
ε = 3.4 was calculated based on the formula below 
(21);  
Statistical analysis. In the statistical analysis, 
the normality of the data was evaluated by 
Kolmogorov-Smirnov test using an SPSS 20 software 
package.  Since the Kolmogorov - Smirnov test 
variable distribution of IgA antibodies in comparison 
with other antibodies exhibited a non-normal 
distribution, in order to compare the means of the 
variables; a non-parametric Mann-Whitney test was 
used. Results were   expressed as the mean ± standard 
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deviation (SD) for each group and P≤0.05 was 
considered statistically significant. 
Results 
The results of the comparison of   the 
demographic and laboratory variables, serum levels 
of IgG, IgM and IgA between case and control 
groups are presented in table 1. 
As depicted in table 1, the average of WBC 
counts in the case and control groups was similar, 
but the average of RBC in the control group was 
significantly different compared with that in case 
group.  Also, the difference between the averages of 
hemoglobin in the two groups was statistically 
significant. The amount of hematocrite in MS 
patients was lower than the average of hematocrit in 
the controls (data not shown) besides, no significant 
difference was observed in the number of platelets. 
Hematological index analysis such as mean 
corpuscular volume (MCV), mean corpuscular 
hemoglobin (MCH), and mean corpuscular 
hemoglobin concentration (MCHC) between the 
two groups had no significant difference  
The results of the total serum antibody showed 
that there was no significant difference in the average 
of total IgM between the case and control groups, 
however difference of the average of total IgA and 
total IgG in these two groups was statistically 
significant. It should be noted that, the averages of 
these antibodies in the control group were 
considerably higher than in MS patients, 
albeit without statistical significance. Based on 
Mann-Whitney test we showed that only the mean 
difference of IgA, RBC and Hb was statistically 
significant between controls and patients. Also, the 
mean differences between IgA and RBC and Hb in 
the two groups were significant statistically but other 
variables had differences that were not statistically 
significant (Table 2). 
In another test, logistic regression was used to 
assess the relationship between age and IgG, with 















Mean  N  








0.9 8.01 8.30 21 case Age 
)years( 15.22 31 21 control 
0.6 0.93 1.52 21 case IgM 
(g/l) 0.38 1.63 21 control 
0.6 4.4 12.84 21 case IgG 
(g/l) 2.4 13.38 21 control 
0.7 2.05 2.50 21 case IgA 
(g/l) 5.06 2.95 21 control 
0.7 90.8 2.44  × 103 21 case Platelets 
mm3)( 55.6 2.35  ×103 21 control 
0.05 0.51 4.4 ×106 21 case RBC 
mm3)( 0.56 4.7 ×106 21 control 
0.9 2.78 7.04 ×103 20 case WBC 
mm3)( 1.6 7.07 ×103 21 control 
 
0.05 
1.5 12.38 20 case Hb 
      (g/dl) 
 
 
1.5 14.79 21 control 
  *P≤0.05 was considered significant  
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n this formula x1 and x2 is the age and IgG, and P 
represents the severity of disease, with each unit 
increase in IgG level, the probability of disease 
exacerbation is 0.22 and with every increase in age 
(years), the probability of disease exacerbation is 
15.0 (Table 3). 
Also, the average levels of antibodies against 
AQP-4 in serum and urine of control group 
compared with the severity of the disease (mild, 
moderate, severe), were not statistically   
significant. This implied that there wasn't much 
difference in the level of antibodies against AQP-4 
in serum and urine of patients with different degrees 
of illness.  Also a comparison between the levels of 
IgG, IgM and IgA in the case group in relation to 
the severity of the disease condition, showed no 
significant difference. Finally, the data of the 
difference between the average levels of IgG, IgM 
and IgA antibodies and antibody against AQP-4 
serum according to severity of disease is summarized 
in (Table 4). 
As shown in table 4, the difference in averages 
between patients with mild and medium MS is equal 
to 1.39, but in mild and severe MS it is equal to 5.93 
and this is useful to analysis the severity of disease. 
We observed a relationship between the average IgG 
levels in the serum of MS patients and degree of the 
disease severity (Figure 1). As depicted in this figure, 
an increase in the degree of illness is associated with 
an increase in the average serum   IgG level; which 
people with more severe disease have the highest 
level of serum IgG. 
Table 2: Comparison of the level of RBC/Hb/IgA between MS patients and controls based on Mann-Whitney test. 
 Hb      (g/dl) 
 
RBC (mm3) IgA (g/l) 
Type N Average 
Rate 
P Average Rate P Average 
Rate 
P 
case 20 17.05 0.03 17.5 0.05 25.76 0.02 
control 21 24.76 24.29 17.24 
 
Table 3: Logistic Regression showing the relation between IgG and age, with severity of disease. 
OR P SE The coefficient of the regression 
line (B) 
 
1.22 0.105 0.122 0.199 IgG(g/l) 
1.15 0.07 0.079 0.142 Age(yeas) 
0.001 0.02 3.22 -7.1 invariant 
 
Table 4: Average difference in levels of IgG, IgM, IgA and Antibodies against AQP-4 in the serum based on the 
severity of the disease condition. 
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Also similar relationship exists between 
serum IgM average levels in patients with MS and 
degree of disease but in an arithmetic progression, 
in such a way that the average IgM level in subjects 
with severe MS, is about double in comparison with 
in subjects with mild MS (Figure 2). 
However, as shown in Table 4, the average 
of IgA level in moderate and mild groups, is 
significantly different from that observed for the 
mild and severe groups .The relationship is 
indirectly proportional between the average serum 
IgA levels and degree of disease, such that patients 
with a higher intensity of MS exhibit lower levels 
of serum IgA, whereas for patients   having a mild 
form of the disease, the reverse is true (Figure 3). 
Also the average of antibody against AQP-4 in 
serum for patients with mild and moderate MS is -
1.54, but that for patients with mild and severe MS is 
3.53. Overall, it was determined that antibodies 
against AQP-4 in urine together with IgG, IgA, RBC, 
platelets, proteins, exhibited a negative correlation 
with age of the patients in the study group,   and also 
had  a direct correlation with other variables. Also 
the average of antibody against AQP-4 in serum for 
patients with mild and moderate MS is -1.54, but that 
for patients with mild and severe MS is 3.53. 
Overall, it was determined that antibodies against 
AQP-4 in urine together with IgG, IgA, RBC, 
platelets, proteins,  exhibited a negative correlation 
with age of the patients in the study group, and also 
had  a direct correlation with other variables. On the 
other hand, antibodies against AQP-4 in urine 
exhibited a direct correlation with platelets, IgM and 
IgG, while they had a direct correlation with the 
other variables like IgA, WBC, RBC, Hb, Hct, and 
patient age. On the other hand, antibodies against 
AQP-4 in urine exhibited a direct correlation with 
platelets, IgM and IgG, while they had a direct 
correlation with the other variables like IgA, WBC, 
RBC, Hb, Hct, and patient age. 
Discussion 
Different studies have been performed to assess the 
role of antibodies against multiple antigens in diagnosis 
and prognosis of MS. Anti-MOG antibodies as the 
 
Figure 1. The relationship between serum IgG average levels in 
patients with MS and degree of disease severity. 
 
 
Figure 2. The relationship between serum IgM average level in 
patients with MS and degree of disease. 
 
 
Figure 3. The relationship between average serum IgA in patients 
with MS and degree of disease. 
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routine method for diagnosing MS disease, are 
appreciable but however, these antibodies can be seen 
in other nervous inflammatory diseases such as 
rheumatoid arthritis.  
The present study assessed the level of antibodies in 
serum and urine of people with MS and their 
correlation with disease prognosis. We made a 
diagnosis based on the level of antibodies to AQP-4 
in serum and urine samples of analyzed groups. In 
this study we assessed the level of total antibodies in 
serum and urine of MS patients and its relation to 
laboratory variables, and disease prognosis.  At the 
same time based on the level of antibodies against 
AQP-4 in serum and urine samples of the patients the 
diagnosis of the disease were analyzed as well. In this 
regard, we observed a significant difference regarding   
hemoglobin in patients and healthy subjects in which 
the control group had higher levels of hemoglobin 
than in patients. Such changes in the hematocrit and 
MCV average were also particularly evident. In terms 
of the level of the variables expressed mentioned 
before it was more appropriate in controls. However, 
in the case of the patients, the level of the variables 
was reduced.  In case of hemoglobin levels, the 
reduction was a significant indicator, since 
hemoglobin levels less than 11 g/dl can be considered 
as a signs of anemia (19). These results were 
consistent with   those of Simpson et al. who 
compared laboratory indices in 15 patients with MS 
and 50 healthy subjects (20). Also in line with our 
study, Ross and colleagues mentioned the role of 
hemoglobin degradation products including met- 
hemoglobin which result to oxidation of sulfydryl 
groups in erythrocyte membrane, and finally damage 
the cell membrane in diseases such as MS, 
Rheumatoid Arthritis. Average of RBC in the control 
group was significantly higher in comparison with 
MS patients .Additionally, control group had a higher 
but non-significantly WBC count compared with MS 
patients. These findings are consistent with the results 
of Simpson et al. because they reported a higher 
average of leukocytes in the group of patients 
compared to a control group (21). 
Our findings indicated that the increase of antibody 
levels in the serum of patients is directly related to   
increasing severity of disease. In addition, increased 
urinary and serum IgG antibodies against AQP-4 is an 
important factor in MS diagnosis. Several studies have 
described the role of antibodies against various 
antigens in the diagnosis and prognosis of MS. 
Anti-MOG antibodies as a routine method for MS 
diagnosis is generally considered however, these 
antibodies with greater intensity can be seen in other 
inflammatory diseases of the nervous system, such as 
rheumatoid arthritis (9). Regression analysis showed 
for every unit increase in the mean total IgGthere is an 
increase in the severity of the disease with a rate of 0.2. 
These results are consistent with those of Shamon et al 
(19). In a study conducted by Ranks G. and colleagues 
on 115 MS patients and 92 healthy individuals, it was 
focused on the genetic and environmental influences on 
allergy and infection (22). Other studies have clarified 
the role of Ig in the pathogenesis of disease. Although 
the type and degree of illness was associated with total 
IgG and related subclasses, genetic polymorphism had 
no association with the disease (23). Also, IgM average 
in the case and control groups had no major difference.  
According to another study by Brett Schneider and 
colleagues, IgM level against the GAGA4 in patients 
with RRMS was greater, than in other diseases of the 
nervous system (24). The result of this study is 
consistent with our study, which indicates an increase 
in antibody is directly related to an increase in the 
severity of illness. In another study, the frequency of 
IgM against auto antigen such as phosphatidylcholine 
ethanol amine, neutrophil cytoplasmic, serine and 
phosphatidylinositol-nuclear antigen in MS patients 
with clinical illness have been reported more than 
others (25). In another study, serum IgM against 
antigens myelin oligodendrocyte glycoprotein and 
myelin basic protein has been reported to predict 
isolated syndrome-CIS conversion to MS disease (26). 
Although the role of antibodies as biochemical markers 
in predicting the disease recurrence or progression of 
MS is substantial, specific antibodies for this purpose 
have not yet been introduced (26). Perhaps some of the 
reasons regarding the differences in IgM level are the 
use of a non-specific antibody in the treatment and 
control groups, small sample size, and chronic nature 
of the disease. However, in our study, the mean total 
IgG as well as IgA in the control group was 
significantly higher than in the treatment group. 
Besides, the survey also showed that although the mean 
IgA in the control group was higher than in the 
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treatment group, the extent of disease in patients with 
severe MS is roughly twice that of patients with mild 
MS. This again confirms that antibody levels have a 
direct correlation with the severity of the disease. This 
finding also applies to the mean   IgM and especially 
IgG, since the rate of increase for both types of 
antibodies in severe MS patients is far more than in 
the case of mild disease.  The frequency of anti- 
AQP-4 IgG above normal range in patients was 80% 
for urine, and 94% for serum respectively, which 
indicated the high level of method sensitivity for 
detecting MS using serum and urine. Average 
antibodies in serum and urine samples had similar 
scores. Hence, the similarity between the average and 
the high frequency of positive reports confirms urine 
as having a diagnostic value roughly equivalent to 
serum levels. However, this result was not consistent 
with the results of Sei Hayat Kawa et al (27). 
Considering the age of the patients,   the mean age of 
patients with severe MS was six years higher than the 
average age in the mild group, indicating greater 
sensitivity of this test in our study. Thus we can 
assume that an average age of 36 years is related to 
disease severity, since disease progression is 
associated with antibody mean.  In another 
perspective, the reduction of total antibodies in 
patients as compared with controls may be attributed 
to the antibody levels. Regression analysis on the 
level of IgG in relation to the severity of the disease 
indicates that a unit increase in the level of antibodies 
corresponds to a two fold increase in the severity of 
the disease. 
Conclusion 
The result of this study indicates that serum antibody 
level is associated with the degree of disease and can 
be used as a prognostic factor. There are equivalent 
numbers of antibodies against AQP-4 in serum and 
urine of MS patients, and sampling of serum and 
urine is reliable method for diagnosis. Urine sampling 
is not an invasive method, and it is easier to collect. 
Given the increasing prevalence of MS and the 
disabilities caused by MS especially in young 
patients, increase awareness and early diagnosis of the 
disease, particularly in clinical settings is important. 
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